Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib vs Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients
NCT00153660Phase 3Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- Jun 2005
- Primary completion
- Nov 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of celecoxib in Peptic ulcer disease (PUD) (2 arms), sponsored by The Chinese University of Hong Kong. Primary endpoint: Recurrent ulcer bleeding at 18 months. Started Jun 2005; status: completed.
02
Drugs
celecoxib
03
Conditions
Peptic ulcer disease (PUD)
Beyond the preview
Go deeper on NCT00153660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00153660.